Patents by Inventor James S. Huston

James S. Huston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5877305
    Abstract: Disclosed is DNA encoding a single-chain Fv (sFv) polypeptide defining a binding site which exhibits the immunological binding properties of an immunoglobulin molecule which binds c-erbB-2 or a c-erbB-2-related tumor antigen, the sFv includes at least two polypeptide domains connected by a polypeptide linker spanning the distance between the C-terminus of one domain and the N-terminus of the other, the amino acid sequence of each of the polypeptide domains includes a set of complementarity determining regions (CDRs) interposed between a set of framework regions (FRs), the CDRs conferring immunological binding to the c-erbB-2 or c-erbB-2-related tumor antigen.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: March 2, 1999
    Assignees: Chiron Corporation, Creative BioMoelcules, Inc.
    Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
  • Patent number: 5861156
    Abstract: Methods of delivering agents to target cells including methods of immunotherapy, are disclosed in which monospecific binding proteins are administered to a host and bind to target cells followed by administration of multivalent antibodies to direct the agents to the target cells.
    Type: Grant
    Filed: January 8, 1993
    Date of Patent: January 19, 1999
    Assignees: Creative BioMolecules, The United States of America as represented by the Department of Health and Human Services
    Inventors: Andrew J. T. George, David M. Segal, James S. Huston
  • Patent number: 5837846
    Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 17, 1998
    Assignees: Creative BioMolecules, Inc., Chiron Corporation
    Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
  • Patent number: 5753204
    Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a preselected antigen by the binding site of each polypeptide chain when administered to a mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 19, 1998
    Assignees: Chiron Corporation, Creative BioMolecules, Inc.
    Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
  • Patent number: 5534254
    Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.
    Type: Grant
    Filed: October 7, 1993
    Date of Patent: July 9, 1996
    Assignees: Chiron Corporation, Creative BioMolecules, Inc.
    Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
  • Patent number: 5525491
    Abstract: Disclosed are serine-rich peptide linkers for linking two or more protein domains to form a fused protein. The peptide linkers contains at least 40% serine residues and preferably have the formula (Ser, Ser,Ser,Ser,Gly).sub.y where y is .gtoreq.1. The resulting fused domains are biologically active together or individually, have improved solubility in physiological media, and improved resistance to proteolysis.
    Type: Grant
    Filed: June 9, 1994
    Date of Patent: June 11, 1996
    Assignee: Creative BioMolecules, Inc.
    Inventors: James S. Huston, Hermann Oppermann, Serge N. Timasheff
  • Patent number: 5482858
    Abstract: Disclosed are a family of synthetic proteins having binding affinity for a preselected antigen, and multifunctional proteins having such affinity. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise V.sub.H -V.sub.L or V.sub.L -V.sub.H -like single chains wherein the V.sub.H and V.sub.L -like sequences are attached by a polypeptide linker, or individual V.sub.H or V.sub.L -like domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function, e.g., as an enzyme, toxin, binding site, or site for attachment to an immobilization media or radioactive atom.
    Type: Grant
    Filed: October 19, 1993
    Date of Patent: January 9, 1996
    Assignee: Creative BioMolecules, Inc.
    Inventors: James S. Huston, Hermann Oppermann
  • Patent number: 5476786
    Abstract: Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise 1) non-covalently associated or disulfide bonded synthetic V.sub.H and V.sub.L dimers, 2) V.sub.H -V.sub.L or V.sub.L -V.sub.H single chains wherein the V.sub.H and V.sub.L are attached by a polypeptide linker, or 3) individual V.sub.H or V.sub.L domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function e.g., as an enzyme, toxin, binding site, or site of attachment to an immobilization media or radioactive atom. Methods are disclosed for producing the proteins, for designing BABS having any specificity that can be elicited by in vivo generation of antibody, and for producing analogs thereof.
    Type: Grant
    Filed: October 19, 1993
    Date of Patent: December 19, 1995
    Assignee: Creative BioMolecules, Inc.
    Inventor: James S. Huston
  • Patent number: 5330902
    Abstract: Disclosed is a novel polypeptide useful as a leader or trailer peptide moiety in recombinant DNA protein production techniques involving fused protein methodology. The polypeptide comprises an amphiphilic helix designed at the DNA level to have hydrophilic charged amino acid residues on one side of the barrel of the helix and nonpolar amino acid residues on the other side of the barrel of the helix. When DNA encoding the helix is attached to a gene encoding a protein of interest, high level expression is achieved and inclusion bodies are spontaneously formed. The inclusion bodies may be collected and purified easily by altering the ionic strength and/or pH of media used to dissolve the inclusion bodies. After purification, the fused protein is cleaved to separate the amphiphilic helix from the product.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: July 19, 1994
    Assignee: Creative BioMolecules, Inc.
    Inventors: Peter C. Keck, Charles M. Cohen, James S. Huston, Richard J. Ridge
  • Patent number: 5302526
    Abstract: Disclosed is a novel polypeptide useful as a leader or trailer peptide moiety in recombinant DNA protein production techniques involving fused protein methodology. The polypeptide comprises an amphiphilic helix designed at the DNA level to have hydrophilic charged amino acid residues on one side of the barrel of the helix and nonpolar amino acid residues on the other side of the barrel of the helix. When DNA encoding the helix is attached to a gene encoding a protein of interest, high level expression is achieved and inclusion bodies are spontaneously formed. The inclusion bodies may be collected and purified easily by altering the ionic strength and/or pH of media used to dissolve the inclusion bodies. After purification, the fused protein is cleaved to separate the amphiphilic helix from the product.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: April 12, 1994
    Assignee: Creative BioMolecules, Inc.
    Inventors: Peter C. Keck, Charles M. Cohen, James S. Huston, Richard J. Ridge
  • Patent number: 5258498
    Abstract: Disclosed are a family of synthetic proteins having binding affinity for a preselected antigen, and multifunctional proteins having such affinity. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS) The sites comprise V.sub.H -V.sub.L or V.sub.L -V.sub.H -like single chains wherein the V.sub.H and V.sub.L -like sequences are attached by a polypeptide linker, or individual V.sub.H or V.sub.L -like domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function, e.g., as an enzyme, toxin, binding site, or site for attachment to an immobilization media or radioactive atom.
    Type: Grant
    Filed: October 1, 1992
    Date of Patent: November 2, 1993
    Assignee: Creative BioMolecules, Inc.
    Inventors: James S. Huston, Hermann Oppermann
  • Patent number: 5243040
    Abstract: Disclosed is a method and a family of materials useful for removing immune complexes from blood preferentially to soluble antibodies. The material comprises analogs of proteins which bind to the Fc region of immunoglobulin. The analogs are produced by truncating or otherwise altering the amino acid sequence of the binding protein to reduce their affinity for Fc. An array of such analogs disposed about the surface of an insoluble matrix has the ability to form multiple points of attachment to the multiple Fc's in a complex so as to bind complex strongly, whereas only weak associations are developed between the Fc region of soluble IgG and individual analogs. The preferred analogs are truncated proteins homologous to a portion of the domains of Protein A or Protein G which bind with Fc. Complex may be removed from whole blood or serum using the material and conventional plasmapheresis techniques.
    Type: Grant
    Filed: November 4, 1991
    Date of Patent: September 7, 1993
    Assignee: Creative BioMolecules
    Inventors: James S. Huston, Lynn Baird, Charles Cohen, Hermann Oppermann
  • Patent number: 5215896
    Abstract: Disclosed is a novel polypeptide useful as a leader or trailer peptide moiety in recombinant DNA protein production techniques involving fused protein methodology The polypeptide comprises an amphiphilic helix designed at the DNA level to have hydrophilic charged amino acid residues on one side of the barrel of the helix and nonpolar amino acid residues on the other side of the barrel of the helix. When DNA encoding the helix is attached to a gene encoding a protein of interest, high level expression is achieved and inclusion bodies are spontaneously formed. The inclusion bodies may be collected and purified easily by altering the ionic strength and/or pH of media used to dissolve the inclusion bodies. After purification, the fused protein is cleaved to separate the amphiphilic helix from the product.
    Type: Grant
    Filed: March 25, 1992
    Date of Patent: June 1, 1993
    Assignee: Creative BioMolecules, Inc.
    Inventors: Peter C. Keck, Charles M. Cohen, James S. Huston, Richard J. Ridge
  • Patent number: 5167824
    Abstract: Disclosed are processes and apparatus for separating a desired solute, such as an optically active isomer, from a complex mixture using carrier facilitated transport in an immobilized liquid membrane or carrier facilitated solvent extraction. The carrier is a binding protein selected and/or engineered to immunochemically reversibly bind to the solute and to have a significant solubility in the extracting solvent or immobilized liquid membrane.
    Type: Grant
    Filed: February 14, 1990
    Date of Patent: December 1, 1992
    Assignees: Creative BioMolecules, Inc., Sepracor, Inc.
    Inventors: Charles Cohen, Robert A. Dishman, James S. Huston, Robert L. Bratzler, David R. Dodds, Charles M. Zepp
  • Patent number: 5132405
    Abstract: Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequencesThe United States government has rights in this invention pursuant to small business innovation research grant number SSS-4 1 R43 CA39870-01 and SSS-4 2 R44 CA39870-02. This application is a continuation of copending application Ser. No. 052,800 filed May 21, 1987.
    Type: Grant
    Filed: June 30, 1988
    Date of Patent: July 21, 1992
    Assignee: Creative BioMolecules, Inc.
    Inventors: James S. Huston, Hermann Oppermann
  • Patent number: 5091513
    Abstract: Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise 1) non-covalently associated or disulfide bonded synthetic V.sub.H and V.sub.L dimers, 2) V.sub.H -V.sub.L or V.sub.L -V.sub.H single chains wherein the V.sub.H and V.sub.L are attached by a polypeptide linker, or 3) individuals V.sub.H or V.sub.L domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function e.g., as an enzyme, toxin, binding site, or site of attachment to an immobilization media or radioactive atom. Methods are disclosed for producing the proteins, for designing BABS having any specificity that can be elicited by in vivo generation of antibody, and for producing analogs thereof.
    Type: Grant
    Filed: January 2, 1991
    Date of Patent: February 25, 1992
    Assignee: Creative BioMolecules, Inc.
    Inventors: James S. Huston, Hermann Oppermann
  • Patent number: 5084398
    Abstract: Disclosed is a method and a family of materials useful for removing immune complexes from blood preferentially to soluble antibodies. The material comprises analogs of proteins which bind to the Fc region of immunoglobulin. The analogs are produced by truncating or otherwise altering the amino acid sequence of the binding protein to reduce their affinity for Fc. An array of such analogs disposed about the surface of an insoluble matrix has the ability to form multiple points of attachment to the multiple Fc's in a complex so as to bind complex strongly, whereas only weak associations are developed between the Fc region of soluble IgG and inidivdual analogs. The preferred analogs are truncated proteins homologous to a portion of the domains of Protein A or Protein G which bind with Fc. Complex may be removed from whole blood or serum using the material and conventional plasmapheresis techniques.
    Type: Grant
    Filed: October 23, 1990
    Date of Patent: January 28, 1992
    Assignee: Creative BioMolecules
    Inventors: James S. Huston, Lynn Baird, Charles Cohen, Hermann Oppermann
  • Patent number: 5013653
    Abstract: Disclosed is a method for the isolation and purification of polypeptides expressed in host cells by recombinant DNA techniques. A fused polypeptide is produced containing a desired polypeptide fused to additional amino acids. The additional amino acids define a leader sequence having properties exploitable in purification, a hinge region, and a cleavage site. The hinge region is cysteine-free and has a secondary structure which serves to expose the cleavage site to a selected endopeptidase. The method of the invention involves the production of a fused polypeptide which may be efficiently isolated by exploiting the properties of the leader sequence, and then efficiently cleaved at the cleavage site in an appropriate aqueous environment by virtue of the influence of the hinge on the cleavage agent/cleavage site reaction and other properties of the fused polypeptide.
    Type: Grant
    Filed: December 28, 1989
    Date of Patent: May 7, 1991
    Assignee: Creative Biomolecules, Inc.
    Inventors: James S. Huston, Marc F. Charette, Charles M. Cohen, Roberto Crea, Peter C. Keck, Hermann Oppermann, David C. Rueger, Richard J. Ridge